Metabolic syndrome and schizophrenia

British Journal of Psychiatry

Volumn 186, Issue JUNE, 2005, Pages 455-456

  Thakore, Jogin H ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

BODY WEIGHT DISORDER; DIET THERAPY; EDITORIAL; HIGH RISK POPULATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LIFESTYLE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; SCHIZOPHRENIA; SCREENING; STRESS; WAIST CIRCUMFERENCE; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MASS SCREENING; METABOLIC SYNDROME X; SCHIZOPHRENIA; STRESS, PSYCHOLOGICAL; WEIGHT GAIN;

EID: 20644463001     PISSN: 00071250     EISSN: None     Source Type: Journal    
DOI: 10.1192/bjp.186.6.455     Document Type: Editorial

References (14)

1. Alberti, K. G. & Zimmet, P. Z. (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: Diagnosis and classification of diabetes mellitus, provisional report of a WHO commission. Diabetic Medicine, 15, 539-553.
2. American Diabetic Association (2004) Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Core, 27, 596-601.
3. Heiskanen, T., Niskanen, L., Lyytikainen, R., et al (2002) Metabolic syndrome in patients with schizophrenia. Journal of Clinical Psychiatry, 64, 575-579.
4. Hellewell, J. S. (1999) Treatment-resistant schizophrenia: reviewing the options and identifying the way forward. Journal of Clinical Psychiatry, 60 (suppl. 23), 14-19.
5. Holsboer, F. (1998) The endocrinology of mental disease. In Clinical Endocrinology (ed. A. Grossman), pp. 1096-1116. Oxford: Blackwell Science.
6. Lieberman, J., Phillips, M., Gu, H., et al (2003) Atypical and conventional antipsychotic drugs in treatment-naive first episode schizophrenia: a 52 week randomized trial of clozapine vs. chlorpromazine. Neuropsychopharmacology, 28, 99-1003.
7. Mukherjee, S., Schnur, D. B. & Reddy, R. (1989) Family history of type 2 diabetes in schizophrenic patients (letter). Lancet, 1, 495.
8. National Cholesterol Education Program (2001) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 258, 2486-2497.
9. Ryan, M. C. M., Collins, P. & Thakore, J. H. (2003) Impaired fasting glucose and elevation of cortisol in drug-naive first-episode schizophrenia. American Journal of Psychiatry, 160, 284-289.
10. Ryan, M. C. M., Flanagan, S., Kinsella, U., et al (2004a) Atypical antipsychotics and visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sciences, 74, 1999-2008.
11. Ryan, M. C. M., Sharifi, N., Condren, R., et al (2004b) Evidence of basal pituitary-adrenal overactivity in first episode, drug naïve patients with schizophrenia. Psychoneuroendocrinology 29, 1065-1070.
12. Thakore, J. H. (ed.) (2001) Physical Consequences of Depression. Cambridge: Wrightson.
13. Thakore, J. H., Vlahoos, J., Martin, A., et al (2002) Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. International Journal of Obesity Related Metabolic Disorders, 26, 137-141.
14. Zhang, Z.-J., Yao, Z.-J., Liu.W, et al (2004) Effects of antipsychotics on fat deposition and changes in leptin and insulin levels: magnetic resonance imaging study of previously untreated people with schizophrenia. British Journal of Psychiatry, 184, 58-62.